DxTerity type I interferon biomarker study, launch bolsters lupus patient stratification

Data supporting the commercial launch of DxTerity’s type I interferon gene expression test in systemic lupus erythematosus (SLE) could lower barriers to signal detection in clinical trials by identifying patients who stand to benefit most from new

Read the full 379 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE